BioCardia, Inc (BCDA) Forward P/S Multiple

BioCardia, Inc. (BCDA) is engaged in a high-risk struggle for regulatory approval of its cardiac therapies. The company's forward P/S visualizes this trajectory, and its current parameter stands at 212.20. The issuer strictly adheres to bioethics and environmental standards during the development of its therapies. However, a critical dependence on a single product leaves the business vulnerable until the completion of final clinical trials.

BCDA (biocardia.com) Forward Price to Sales history from 07/04/2022 to 05/15/2025

BioCardia Inc - analytical breakdowns and key metrics (BCDA)

- current price and projected stock value:

Stock Price BioCardia|BCDA - Analyst Median Target

- market capitalization details:

Market Capitalization BioCardia Inc|BCDA - Enterprise Value

- issuer book value statistics:

Accounting Value per Share BioCardia|BCDA - Accounting Value of Company|Market Capitalization to Book Value Ratio biocardia.com|BCDA - Company Total Asset Base

- issuer credit burden and liquidity indicators:

- net income and valuation multiples indicators:

BCDA - Net Income|Projected Future Earnings BioCardia, Inc.|BCDA - Price to Earnings Multiple|Forward P/E Multiple BioCardia, Inc|BCDA - PEG Multiple|EV/EBITDA Multiple BioCardia Inc|BCDA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) BioCardia|BCDA - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth biocardia.com|BCDA - Earnings growth in current year|Net earnings per share growth forecast for next year BioCardia, Inc.

- company sales and revenue statistics:

BCDA - Company Sales Revenue|Company Future Sales Volume BioCardia|BCDA - Market Cap to Sales Volume|Forward P/S Multiple BioCardia Inc

Analysis of all company metrics:BioCardia (BCDA)

The indicator is calculated as the ratio of current market capitalization to projected revenue, reflecting market expectations regarding future cash flows and the valuation's sensitivity to financial forecasts. By analyzing the future P/S multiple, an investor can identify irrational price fluctuations amid fierce competition in the cardiac cell therapy sector, where regulatory rejection risks directly impact the investment attractiveness of BioCardia, Inc. (BCDA).

Analysis of competing companies

Forward P/S Multiple REGN (Regeneron)|Market Cap to Expected Sales Ratio iRhythm Technologies, Inc. (IRTC)|Lantheus Medical Imaging - Forward P/S Multiple|MLYS - Forward P/S Multiple|HTFL (heartflow.com) - Forward Price-to-Revenue Multiple|kestramedical.com - Forward Price to Sales|ESPR (Esperion) - Forward P/S Multiple|Amarin Corporation (AMRN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Anteris Technologies Global (AVR)|tenayatherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple CVRX (CVRx, Inc.)|MIST - Forward Price-to-Revenue Multiple|CRDL: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio HeartBeam Inc BEAT|TENX: Forward P/S Multiple|ADGM (Adagio Medical, Inc.) - Price-to-Projected Revenue Ratio|VTAK (Catheter Precision) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ARCA Bio (ABIO)|Forward P/S Multiple ACST|Aerovate Therapeutics Inc. - Market Cap to Projected Revenue|Forward P/S Multiple VERV (Verve Therapeutics, Inc.)|Forward P/S Multiple Windtree Therapeutics Inc. WINT